121 related articles for article (PubMed ID: 38837144)
21. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomised, double-blind, placebo-controlled, phase II/III clinical study in patients aged ≥13 years.
Yokozeki H; Murota H; Matsumura T; Komazaki H;
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38629497
[TBL] [Abstract][Full Text] [Related]
22. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
Paller AS; Flohr C; Cork M; Bewley A; Blauvelt A; Hong HC; Imafuku S; Schuttelaar MLA; Simpson EL; Soong W; Arlert P; Lophaven KW; Kurbasic A; Soldbro L; Vest NS; Wollenberg A
JAMA Dermatol; 2023 Jun; 159(6):596-605. PubMed ID: 37074705
[TBL] [Abstract][Full Text] [Related]
26. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
Ständer S; Bhatia N; Gooderham MJ; Silverberg JI; Thyssen JP; Biswas P; DiBonaventura M; Romero W; Farooqui SA
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1308-1317. PubMed ID: 35462428
[TBL] [Abstract][Full Text] [Related]
27. Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.
Stander S; Kim BS; Guillemin I; Rhoten S; Wratten S; Brookes E; O'Malley JT; Bansal A; Msihid J; Thomas R; Bahloul D
J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1401-1409. PubMed ID: 38329222
[TBL] [Abstract][Full Text] [Related]
28. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
29. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
[TBL] [Abstract][Full Text] [Related]
31. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
32. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Johnson S; Farooqui SA; Kerkmann U; Clibborn C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2056-2066. PubMed ID: 37335885
[TBL] [Abstract][Full Text] [Related]
33. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
Sadik CD; Rashid H; Hammers CM; Diercks GFH; Weidinger A; Beissert S; Schauer F; Fettiplace J; Thaçi D; Ngai Y; Nunn MA; Zillikens D; Horváth B
JAMA Dermatol; 2022 Jun; 158(6):641-649. PubMed ID: 35507334
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
Meher BR; Mohanty RR; Padhy BM
J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
[TBL] [Abstract][Full Text] [Related]
36. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
37. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
Paller AS; Silverberg JI; Cork MJ; Guttman-Yassky E; Lockshin B; Irvine AD; Kim MB; Kabashima K; Chen Z; Lu Y; Bansal A; Rossi AB; Shabbir A
JAMA Dermatol; 2023 Mar; 159(3):255-266. PubMed ID: 36723913
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Zirwas MJ; Draelos ZD; DuBois J; Kircik LH; Moore AY; Stein Gold L; Alonso-Llamazares J; Bukhalo M; Bruce S; Eads K; Green LJ; Guenthner ST; Ferris LK; Forman SB; Kempers SE; Lain E; Lynde CW; Pariser DM; Toth DP; Yamauchi PS; Higham RC; Krupa D; Burnett P; Berk DR
JAMA Dermatol; 2023 Jun; 159(6):613-620. PubMed ID: 37133856
[TBL] [Abstract][Full Text] [Related]
40. Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate‑to‑severe atopic dermatitis in randomized, double‑blind and placebo‑controlled trials: A systematic review and a meta‑analysis.
Xie X; Zhang J; Huang F; Fan L
Biomed Rep; 2024 May; 20(5):84. PubMed ID: 38628626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
